Axsome Therapeutics (NASDAQ:AXSM) Given “Buy” Rating at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report sent to investors on Tuesday morning, AnalystRatings.com reports.
Other research analysts have also recently issued reports about the stock. LADENBURG THALM/SH SH reiterated a buy rating and issued a $165.00 target price (up from $139.00) on shares of Axsome Therapeutics in a research note on Tuesday, January 14th. SunTrust Banks lifted their price target on shares of Axsome Therapeutics to $140.00 and gave the stock a buy rating in a report on Thursday, January 2nd. BTIG Research increased their price objective on Axsome Therapeutics to $97.00 and gave the company a buy rating in a report on Monday, December 30th. Zacks Investment Research raised Axsome Therapeutics from a sell rating to a hold rating in a research report on Tuesday, November 19th. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $125.00 target price (up from $104.00) on shares of Axsome Therapeutics in a research report on Monday, December 30th. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $99.80.
Shares of NASDAQ AXSM traded down $0.02 during mid-day trading on Tuesday, reaching $88.71. 28,706 shares of the company’s stock were exchanged, compared to its average volume of 970,147. The firm has a 50-day moving average price of $82.08 and a two-hundred day moving average price of $39.69. The company has a debt-to-equity ratio of 2.80, a current ratio of 2.39 and a quick ratio of 2.39. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -55.20 and a beta of 3.39. Axsome Therapeutics has a 52 week low of $7.63 and a 52 week high of $109.94.
Several hedge funds and other institutional investors have recently bought and sold shares of AXSM. NEXT Financial Group Inc purchased a new stake in shares of Axsome Therapeutics during the 4th quarter valued at approximately $31,000. Huntington National Bank purchased a new position in Axsome Therapeutics in the 4th quarter valued at approximately $52,000. Rhumbline Advisers grew its stake in Axsome Therapeutics by 1.7% in the 3rd quarter. Rhumbline Advisers now owns 31,799 shares of the company’s stock valued at $644,000 after buying an additional 525 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in Axsome Therapeutics by 3.5% during the 3rd quarter. Janney Montgomery Scott LLC now owns 28,475 shares of the company’s stock valued at $576,000 after acquiring an additional 950 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. raised its holdings in Axsome Therapeutics by 41.2% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the company’s stock valued at $124,000 after acquiring an additional 1,400 shares during the period. 54.64% of the stock is currently owned by institutional investors.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Further Reading: Cost of Goods Sold (COGS)
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.